A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility, efficacy and safety of adding
bevacizumab to rituximab compared to rituximab alone in patients with previously treated
follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one
previous chemotherapy regimen and not more than 2 previous chemotherapy regimens.